On September 8, 2022 Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that three posters have been accepted for data presentation at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting (Press release, Kintara Therapeutics, SEP 8, 2022, View Source [SID1234619234]). The 2022 SNO Annual Meeting will be held from November 16 through November 20, 2022 in Tampa, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data Presentations:

Phase 2 Study of VAL-083 and Radiotherapy in Newly-Diagnosed, MGMT-unmethylated GBM
Poster Presenter: Zhongping Chen, MD, Ph.D. – Sun Yat-sen University Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)

Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access: A Case Report
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)

VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center
(Presentation Time: Friday, November 18, 2022 – 7:30 to 9:30 pm ET)